Managing Partner, Flic Gabbay is delighted to annouce the appointment of John Fox to the team. John has almost 30 years of experience in the pharmaceutical industry working in multinational pharmaceutical companies, biotechs and CROs. After joining the industry with Eli Lilly, his early career was spent mainly in clinical research, but time in early stage companies has added experience across all drug development functions. After serving in Shire Pharmaceuticals in increasingly senior R&D roles, culminating as Director of Planning, he co-founded a start-up to take a portfolio of university technologies into development. Hunter Fleming raised venture funds enabling it to take several compounds to Phase I/II clinical trials before it was eventually acquired in 2008. At this time John joined Merrion Pharmaceuticals, a drug delivery company listed on the Irish Stock Exchange, where he served as both Chief Development Officer and Chief Executive before joining Transcrip.
John’s career has covered a variety of therapeutic areas, including CNS, oncology, Metabolic Bone Disease and renal disease. This has involved directing relevant development functions from bench to Phase III and coordination of activities across a portfolio in support of strategic objectives.
John graduated with a BSc in Biochemistry from Queens University Belfast in 1977. Following completion of his PhD in Prenatal Diagnosis of Inborn Errors of Metabolism and a period in the Department of Therapeutics at Queens working in the areas of drug utilisation research and healthy volunteer Phase I studies, he joined the pharmaceutical industry in 1987. John subsequently undertook an MBA degree at Henley Management College, graduating in 1994.
With an interest in commercialisation of strong science, John has served as a non-executive director for Southampton Innovations and has conducted a number of commercial evaluations of new projects from both industry and academic sources. He has also been involved as a coach and mentor facilitating entrepreneurship in healthcare. He is a member of the American Society for Clinical Oncology and the Institute of Directors (UK).